过去20年全国真实世界小细胞肺癌特征与结局:免疫治疗对真实世界总生存的影响
法国非学术公立医院每十年开展的前瞻性多中心KBP队列研究,比较2000、2010、2020三个队列中小细胞肺癌患者的特征与结局。2020队列中SCLC占12.6%,女性比例升至35.7%;全部SCLC患者1年OS率从2000年34.4%升至2020年38.4%。广泛期患者经熵平衡加权多因素分析,化疗联合免疫治疗中位OS为11.1个月,单纯化疗为8.1个月(HR 0.62,p<0.001)。
要点
- SCLC占肺癌比例从2000年16.4%降至2010年13.5%和2020年12.6%。
- 女性SCLC患者比例从2000年15.5%升至2020年35.7%。
- 广泛期SCLC化疗联合免疫治疗较单纯化疗改善中位OS(11.1 vs 8.1个月,HR 0.62)。
核心结论
- SCLC比例随时间下降,但女性比例上升;20年间全部SCLC患者1年OS率改善;KBP-2020队列提示真实世界中免疫治疗对广泛期SCLC的OS有获益。
研究设计与样本
- KBP研究为自2000年起每十年在法国非学术公立医院开展的真实世界、前瞻性、多中心队列研究。
- 本研究采用相同方法分析三个前瞻性队列,描述并比较SCLC患者的特征与结局,重点关注2020队列的治疗。
- 2020队列共纳入8999例肺癌患者,其中1137例为SCLC。
主要发现
- SCLC患者比例从2000年16.4%降至2010年13.5%和2020年12.6%。
- 女性SCLC患者比例从2000年15.5%升至2020年35.7%。
- 15.4%的SCLC患者为局限期,84.6%为广泛期。
- 全部SCLC患者1年OS率从2000年34.4%升至2020年38.4%。
- 广泛期SCLC经熵平衡加权多因素分析(纳入年龄、性别、体能状态、转移部位数、脑转移),中位OS从单纯化疗8.1个月改善至化疗联合免疫治疗11.1个月(HR 0.62,p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The KBP studies are real-life nationwide, prospective, multicenter cohort studies of patients diagnosed with primary lung cancer that have been conducted in French non-academic public hospitals each decade since 2000. METHODS: Patients were analyzed in three prospective cohorts using the same methodology. In this study, we describe and compare the characteristics and outcomes of patients with small cell lung cancer (SCLC), with a focus on treatments in the 2020 cohort. FINDINGS: 8999 patients with lung cancer were included in the 2020 cohort, of whom 1137 had SCLC. From 2000 to 2010 and 2020, the proportion of patients with SCLC decreased from 16.4 % to 13.5 % and 12.6 % respectively. Between 2000 and 2020, the proportion of women increased from 15.5 % to 35.7 %. 15.4 % of patients with SCLC had limited-stage (LS) disease and 84.6 % of patients had extensive-stage (ES) disease. The 1-year overall survival (OS) rate for all patients with SCLC increased from 34.4 % in 2000 to 38.4 % in 2020. For ES-SCLC, multivariate analysis weighted with "entropy balancing" by including age, sex, performance status, number of metastatic sites, and brain metastases indicated an improvement in median OS from 8.1 months in patients receiving chemotherapy only to 11.1 months in patients receiving chemotherapy plus immunotherapy (HR 0.62, p < 0.001). INTERPRETATION: The proportion with SCLC has decreased over time, but the proportion of women has increased. The 1-year OS rates have improved over 20 years. The KBP-2020 cohort suggests a benefit of immunotherapy on OS in patients with ES-SCLC in the real-life setting.
引用
- Falchero L, Meyer N, Molinier O, et al. Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting. Eur J Cancer. 2024. PMID: 39168000. doi:10.1016/j.ejca.2024.114277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。